Top 10 Psychedelic Papers on Microdosing

The observational study examines the effects of microdosing psychedelics on psychological functioning over six weeks. It found increased functioning on dosing days, reduced depression and stress, lower distractibility, increased absorption, and increased neuroticism. A second study reveals a discrepancy between expected and reported benefits, highlighting the need for controlled research. It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

Using a self‑blinding citizen‑science protocol in the largest placebo‑controlled microdosing study to date, the authors found psychological outcomes improved after four weeks but with no significant differences between microdose and placebo groups. Small acute and anxiety effects appeared due to participants breaking blind, suggesting reported benefits of microdosing are largely placebo‑driven and demonstrating the feasibility of a low‑cost self‑blinding approach. It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone.

The observational study explores the cognitive-enhancing potential of microdosing psychedelic truffles in healthy adults. It found improved convergent and divergent thinking performance after a microdose, though fluid intelligence remains unaffected. It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

This double-blind, placebo-controlled, within-subject study found that a microdose of LSD elicited dose-dependent subjective effects during the 'peak' of the experience but not at the follow-up (48 hours). It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

The survey study included the Unusual Uses Tasks as a proxy for divergent creativity. They found that people who microdosed psychedelics and psilocybin ) were more creative. It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

In a randomised, double‑blind, placebo‑controlled trial in older adults, oral microdoses of LSD produced reliable over‑reproduction (temporal dilation) of intervals ≥2000 ms, most pronounced at 10 μg, despite no robust subjective changes in perception, mentation or concentration. Hierarchical regression indicated this suprasecond timing effect was independent of marginal self‑reported drug effects, suggesting a direct influence of microdose LSD on interval timing. For readers, the value is not just the result but the study design: it shows how psychedelic microdosing performs when tested under more structured clinical conditions.

The rat study investigated the effects of microdosing DMT in rats and found that a chronic (∼2 months), intermittent (every third day) microdosing regimen facilitated fear extinction learning and reduced depressive immobility in the forced swim test without producing the anxiety-like effects characteristic of a high dose. It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

The qualitative interview study of 21 male psychedelic microdosers found many deliberately used sub‑perceptual doses in phases to enhance everyday functioning, reporting improvements in mood, cognition and creativity that helped counter anxiety and depression, although some experienced challenges or stopped. The findings are not generalisable but may inform future research questions and hypotheses. It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

In a prospective web-based study of 81 participants following a four-week psychedelic microdosing regimen, self-reported psychological well‑being, emotional stability, resilience and reductions in anxiety and depressive symptoms were observed. However, baseline positive expectancies strongly predicted these improvements, indicating a substantial placebo contribution and cautioning against strong therapeutic claims. It adds a concrete angle on psychedelic microdosing, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

In a phase 1 double‑blind, placebo‑controlled trial in 48 healthy older volunteers (mean age 62. 9), oral low doses of LSD given every fourth day for 21 days produced undetectable plasma levels at 5 μg and 30‑minute peak concentrations at 10 and 20 μg. The regimen was well tolerated with adverse event rates similar to placebo and no detectable impairment of cognition, balance or proprioception, supporting further evaluation of LSD for prevention or treatment of Alzheimer’s disease. It is a useful counterweight to efficacy-focused papers because it keeps attention on screening, monitoring, and the conditions under which treatment can be used responsibly.